OptimizeRx OPRX Insider Ownership

Updated Oct 10, 2026

Over the past 12 months, OptimizeRx insiders sold $18,752 of stock on the open market (1.39K shares) and made no open-market purchases.

• The largest open-market sales of OPRX in the past 12 months were by Edward Stelmakh (Chief Finance & Strategy Officer), totaling $18,752 (1.39K shares), most recently on December 19, 2025.
• Apart from open-market trades, OPRX insiders received 201.63K shares in stock awards, acquired 21.68K shares through option exercises and conversions and gave up 42.7K shares to cover taxes or exercise prices in the past 12 months.
• Per Business Quant, OPRX insiders together hold 2.06Mn shares based on their latest Form 4 filings, up 2.43% from 2.01Mn shares at the end of Q2 2026 and up 11.30% from 1.85Mn shares at the end of Q3 2025.
• OPRX's insiders hold all 2.06Mn shares directly, in their own names, with no indirect holdings.
• Holdings in OptimizeRx stock are reported by 14 insiders, the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• OPRX's largest insider holders by reported holdings are William J. Febbo (CEO, 600.85K shares), James Paul Lang (Director, 433.84K shares) and Stephen L. Silvestro (Chief Executive Officer, 183.55K shares).
• William J. Febbo alone accounts for 29.21% of the shares held by OptimizeRx insiders.
• Institutional investors held 59.51% of OptimizeRx stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 10.92%; other investors, including the public, hold roughly 29.57%.
• In the last 12 months, 38 Form 4 filings with transactions in OPRX stock came from 13 insiders.
• The insider holdings and trades above for OptimizeRx reflect Form 4 filings through October 2, 2026.